In northern hemispheres, October heralds the onset of autumn and we are reminded that its cool breezes will soon blow wintry as 1996 draws to a close. Tempus fugit! The swift passage of time also reminds us that the first volume of The Oncologist will soon conclude with its sixth issue in December.
However, before 1996 becomes history, let’s pause and reflect on the pledges we made to our readership at the beginning of the year. The Founding Editors conceived the Journal to provide authoritative, topical, innovative articles in an attractive format for a very special reader: the busy, practicing physician who cares for cancer patients.
 STA-21 |
|
B6175-1 |
ApexBio |
1 mg |
EUR 201.6 |
|
|
|
Description: JAK/STAT Signaling|STAT |
STA-21 |
|
B6175-5 |
ApexBio |
5 mg |
EUR 1299.6 |
|
Description: IC50: 12.2 ?M for DU145 cellsSTA-21 is a STAT3 inhibitor.STAT-3, a transcription factor encoded by the STAT-3 gene, exists in a latent form in the cytoplasm. |
 sta Antibody |
|
CSB-PA604967XA01DMO-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila teissieri (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA604967XA01DMO-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila teissieri (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA606360XA01DMJ-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila simulans (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA606360XA01DMJ-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila simulans (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DKY-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila ananassae (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DKY-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila ananassae (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DLK-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila erecta (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DLK-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila erecta (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DLU-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila melanogaster (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DLU-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila melanogaster (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DMG-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila sechellia (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DMG-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila sechellia (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DMR-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila yakuba (Fruit fly) sta protein |
sta Antibody |
|
CSB-PA020485XA01DMR-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Drosophila yakuba (Fruit fly) sta protein |
 STA Macrobeads |
|
MB-4701-2 |
EY Laboratories |
1 Each |
Ask for price |
|
Description: STA Macrobeads . With the exception of Diagnostic Microbiology Products all biochemicals described are for research use only. The biochemical reagents are not designed for use in therapeutic or diagnostic applications. We are unable to ship to individuals. Please place all orders through an established firm or institution. Nothing disclosed is to be construed as a recommendation to use our products in violation of any patents. All research products are offered without warranty or guarantee, since the ultimate condition of use and the variability in material handling are beyond our control. |
) Ganetespib (STA-9090) |
|
A4385-10 |
ApexBio |
10 mg |
EUR 108 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Ganetespib (STA-9090) |
|
A4385-200 |
ApexBio |
200 mg |
EUR 800 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Ganetespib (STA-9090) |
|
A4385-5 |
ApexBio |
5 mg |
EUR 76 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Ganetespib (STA-9090) |
|
A4385-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 76 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Ganetespib (STA-9090) |
|
A4385-50 |
ApexBio |
50 mg |
EUR 167.2 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Ganetespib (STA-9090) |
|
A4385-S |
ApexBio |
Evaluation Sample |
EUR 24 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
) Elesclomol (STA-4783) |
|
A4386-10 |
ApexBio |
10 mg |
EUR 79.2 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Elesclomol (STA-4783) |
|
A4386-200 |
ApexBio |
200 mg |
EUR 448 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Elesclomol (STA-4783) |
|
A4386-5 |
ApexBio |
5 mg |
EUR 52.8 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Elesclomol (STA-4783) |
|
A4386-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 64 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Elesclomol (STA-4783) |
|
A4386-50 |
ApexBio |
50 mg |
EUR 176 |
|
|
|
Description: Metabolism|HSP#Proteases|HSP |
Ganetespib (STA-9090) |
|
9459-25 |
Biovision |
each |
EUR 705.6 |
Ganetespib (STA-9090) |
|
9459-5 |
Biovision |
each |
EUR 222 |
Elesclomol (STA-4783) |
|
27748-1 |
BPS Bioscience |
5 mg |
EUR 180 |
|
Description: Elesclomol is a HSP-90 Inhibitor with pro-apoptotic and potential antineoplastic activities. Elesclomol induces oxidative stress and triggers mitochondrial-induced apoptosis in cancer cells. |
Elesclomol (STA-4783) |
|
27748-2 |
BPS Bioscience |
10 mg |
EUR 290 |
|
Description: Elesclomol induces oxidative stress and triggers mitochondrial-induced apoptosis in cancer cells. |
Ganetespib (STA-9090) |
|
27750-2 |
BPS Bioscience |
10 mg |
EUR 280 |
|
Description: Ganetespib (also known as STA-9090) is a potent small-molecule inhibitor of heat shock protein 90 (IC50=4 nM). It binds to the ATP pocket in the N-terminus of Hsp90, resulting in down-regulation of Hsp90 client protein levels. Being structurally unrelated to geldanamycin-derived Hsp90 inhibitors (17-AAG, 17-DMAG, and IPI-504), ganetespib has a unique triazolone-containing chemical structure and stands out other Hsp90 inhibitors in terms of potency, antitumor activity, and safety profile. |
Elesclomol (STA-4783) |
|
B1815-25 |
Biovision |
each |
EUR 764.4 |
Elesclomol (STA-4783) |
|
B1815-5 |
Biovision |
each |
EUR 235.2 |
Elesclomol (STA-4783) |
|
MBS386217-100mg |
MyBiosource |
100mg |
EUR 1150 |
Elesclomol (STA-4783) |
|
MBS386217-10mg |
MyBiosource |
10mg |
EUR 240 |
Elesclomol (STA-4783) |
|
MBS386217-50mg |
MyBiosource |
50mg |
EUR 750 |
Elesclomol (STA-4783) |
|
MBS386217-5mg |
MyBiosource |
5mg |
EUR 190 |
Elesclomol (STA-4783) |
|
MBS386217-5x100mg |
MyBiosource |
5x100mg |
EUR 5175 |
Ganetespib (STA-9090) |
|
MBS386218-100mg |
MyBiosource |
100mg |
EUR 360 |
Ganetespib (STA-9090) |
|
MBS386218-10mg |
MyBiosource |
10mg |
EUR 190 |
Ganetespib (STA-9090) |
|
MBS386218-50mg |
MyBiosource |
50mg |
EUR 260 |
Ganetespib (STA-9090) |
|
MBS386218-5mg |
MyBiosource |
5mg |
EUR 160 |
Ganetespib (STA-9090) |
|
MBS386218-5x100mg |
MyBiosource |
5x100mg |
EUR 1600 |
Elesclomol (STA-4783) |
|
MBS578735-100mg |
MyBiosource |
100mg |
EUR 320 |
Elesclomol (STA-4783) |
|
MBS578735-10mg |
MyBiosource |
10mg |
EUR 165 |
Elesclomol (STA-4783) |
|
MBS578735-50mg |
MyBiosource |
50mg |
EUR 230 |
Elesclomol (STA-4783) |
|
MBS578735-5mg |
MyBiosource |
5mg |
EUR 145 |
Elesclomol (STA-4783) |
|
MBS578735-5x100mg |
MyBiosource |
5x100mg |
EUR 1290 |
Ganetespib (STA-9090) |
|
MBS577870-10mg |
MyBiosource |
10mg |
EUR 170 |
Ganetespib (STA-9090) |
|
MBS577870-25mg |
MyBiosource |
25mg |
EUR 180 |
Ganetespib (STA-9090) |
|
MBS577870-2mg |
MyBiosource |
2mg |
EUR 135 |
Ganetespib (STA-9090) |
|
MBS577870-50mg |
MyBiosource |
50mg |
EUR 225 |
Ganetespib (STA-9090) |
|
MBS577870-5mg |
MyBiosource |
5mg |
EUR 150 |
) Ganetespib (STA 9090) |
|
MBS132414-100mg |
MyBiosource |
100mg |
EUR 1065 |
Ganetespib (STA 9090) |
|
MBS132414-500mg |
MyBiosource |
500mg |
EUR 2775 |
 sta-1 Antibody |
|
CSB-PA863098XA01CXY-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Caenorhabditis elegans sta-1 protein |
sta-1 Antibody |
|
CSB-PA863098XA01CXY-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Caenorhabditis elegans sta-1 protein |
 sta-2 Antibody |
|
CSB-PA631335XA01CXY-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Caenorhabditis elegans sta-2 protein |
sta-2 Antibody |
|
CSB-PA631335XA01CXY-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Caenorhabditis elegans sta-2 protein |
 StA-IFN-1 |
|
MBS5798889-5x25mg |
MyBiosource |
5x25(mg |
EUR 5040 |
) Solanum tuberosum (STA, potato) |
|
MBS613204-1mL |
MyBiosource |
1mL |
EUR 425 |
Solanum tuberosum (STA, potato) |
|
MBS613204-5x1mL |
MyBiosource |
5x1mL |
EUR 1765 |
) Solanum tuberosum (STA, Potato) |
|
MBS655995-5mg |
MyBiosource |
5mg |
EUR 590 |
Solanum tuberosum (STA, Potato) |
|
MBS655995-5x5mg |
MyBiosource |
5x5mg |
EUR 2500 |
 PHA 408 |
|
HY-14180 |
MedChemExpress |
10 mg |
EUR 378.79 |
|
Description: PHA 408 (PHA-408) is a potent, selective and orally active IκB kinase-2 (IKK-2) inhibitor. PHA 408 is a powerful anti-inflammatory agent against lipopolysaccharide (LPS)- and cigarette smoke (CS)-mediated lung inflammation[1]. |
) Recombinant Streptothricin acetyltransferase (sta) |
|
MBS1133897-005mgBaculovirus |
MyBiosource |
0.05mg(Baculovirus) |
EUR 1030 |
Recombinant Streptothricin acetyltransferase (sta) |
|
MBS1133897-005mgEColi |
MyBiosource |
0.05mg(E-Coli) |
EUR 705 |
Recombinant Streptothricin acetyltransferase (sta) |
|
MBS1133897-005mgYeast |
MyBiosource |
0.05mg(Yeast) |
EUR 860 |
Recombinant Streptothricin acetyltransferase (sta) |
|
MBS1133897-02mgEColi |
MyBiosource |
0.2mg(E-Coli) |
EUR 915 |
Recombinant Streptothricin acetyltransferase (sta) |
|
MBS1133897-05mgEColi |
MyBiosource |
0.5mg(E-Coli) |
EUR 1005 |
 Isovaleryl-Phe-Nle-Sta-Ala-Sta-OH |
|
H-5435.0001 |
Bachem |
1.0mg |
EUR 428.4 |
|
Description: Sum Formula: C39H65N5O9; CAS# [98092-14-9] |
Isovaleryl-Phe-Nle-Sta-Ala-Sta-OH |
|
H-5435.0005 |
Bachem |
5.0mg |
EUR 1603.2 |
|
Description: Sum Formula: C39H65N5O9; CAS# [98092-14-9] |
 (PE)) EMD (Emerin, STA, EDMD) (PE) |
|
MBS6157627-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
EMD (Emerin, STA, EDMD) (PE) |
|
MBS6157627-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
) EMD, CT (Emerin, STA, EDMD) |
|
MBS649006-02mL |
MyBiosource |
0.2mL |
EUR 695 |
EMD, CT (Emerin, STA, EDMD) |
|
MBS649006-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
 (AP)) EMD (Emerin, STA, EDMD) (AP) |
|
MBS6131112-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
EMD (Emerin, STA, EDMD) (AP) |
|
MBS6131112-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 APC) EMD (Emerin, STA, EDMD) APC |
|
MBS6136415-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
EMD (Emerin, STA, EDMD) APC |
|
MBS6136415-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (HRP)) EMD (Emerin, STA, EDMD) (HRP) |
|
MBS6152324-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
EMD (Emerin, STA, EDMD) (HRP) |
|
MBS6152324-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (FITC)) EMD (Emerin, STA, EDMD) (FITC) |
|
MBS6147021-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
EMD (Emerin, STA, EDMD) (FITC) |
|
MBS6147021-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 Human STA-IgM ELISA Kit |
|
MBS3801995-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Human STA-IgM ELISA Kit |
|
MBS3801995-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Human STA-IgM ELISA Kit |
|
MBS3801995-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Human STA-IgM ELISA Kit |
|
MBS3801995-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 Human STA-IgG ELISA Kit |
|
MBS3803368-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Human STA-IgG ELISA Kit |
|
MBS3803368-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Human STA-IgG ELISA Kit |
|
MBS3803368-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Human STA-IgG ELISA Kit |
|
MBS3803368-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 (Biotin)) EMD (Emerin, STA, EDMD) (Biotin) |
|
MBS6141718-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
EMD (Emerin, STA, EDMD) (Biotin) |
|
MBS6141718-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (AP)) Solanum tuberosum (STA, potato) (AP) |
|
MBS610999-1mg |
MyBiosource |
1mg |
EUR 585 |
Solanum tuberosum (STA, potato) (AP) |
|
MBS610999-5x1mg |
MyBiosource |
5x1mg |
EUR 2475 |
 (AP)) Solanum tuberosum (STA, Potato) (AP) |
|
MBS656714-1mg |
MyBiosource |
1mg |
EUR 585 |
Solanum tuberosum (STA, Potato) (AP) |
|
MBS656714-5x1mg |
MyBiosource |
5x1mg |
EUR 2475 |
 GlycoBind Binding Buffer - STA/STL |
|
21510914-1 |
Bio-WORLD |
- |
EUR 22.88 |
GlycoBind Binding Buffer - STA/STL |
|
21510914-2 |
Bio-WORLD |
- |
EUR 50.5 |
GlycoBind Binding Buffer - STA/STL |
|
21510914-3 |
Bio-WORLD |
- |
EUR 77.36 |
 GlycoElute Elution Buffer - STA/STL |
|
21511311-1 |
Bio-WORLD |
- |
EUR 33.57 |
GlycoElute Elution Buffer - STA/STL |
|
21511311-2 |
Bio-WORLD |
- |
EUR 54.91 |
GlycoElute Elution Buffer - STA/STL |
|
21511311-3 |
Bio-WORLD |
- |
EUR 79.47 |
 (FITC)) Solanum tuberosum (STA, Potato) (FITC) |
|
MBS656550-2mg |
MyBiosource |
2mg |
EUR 510 |
Solanum tuberosum (STA, Potato) (FITC) |
|
MBS656550-5x2mg |
MyBiosource |
5x2mg |
EUR 2135 |
 -STA-) Crude Solanum tuberosum (Potato) -STA- |
|
L-4700-100 |
EY Laboratories |
100 mg |
Ask for price |
|
Description: Crude Solanum tuberosum (Potato) -STA-, 100mg Product volume may vary.
With the exception of Diagnostic Microbiology Products all biochemicals described are for research use only. The biochemical reagents are not designed for use in therapeutic or diagnostic applications. We are unable to ship to individuals. Please place all orders through an established firm or institution. Nothing disclosed is to be construed as a recommendation to use our products in violation of any patents. All research products are offered without warranty or guarantee, since the ultimate condition of use and the variability in material handling are beyond our control. |
 (Biotin)) Solanum tuberosum (STA, Potato) (Biotin) |
|
MBS656164-2mg |
MyBiosource |
2mg |
EUR 530 |
Solanum tuberosum (STA, Potato) (Biotin) |
|
MBS656164-5x2mg |
MyBiosource |
5x2mg |
EUR 2230 |
 Pepstatin, acetylated [Ac-Val-Val-Sta-Ala-Sta] |
|
MBS658864-1mg |
MyBiosource |
1mg |
EUR 750 |
Pepstatin, acetylated [Ac-Val-Val-Sta-Ala-Sta] |
|
MBS658864-5x1mg |
MyBiosource |
5x1mg |
EUR 3235 |
 MagSi-STA 1.0 |
|
MD01001 |
AMSBIO |
2 mL |
EUR 426 |
MagSi-STA 1.0 |
|
MD03001 |
AMSBIO |
10 mL |
EUR 1434 |
MagSi-STA 1.0 |
|
MD04001 |
AMSBIO |
100 mL |
EUR 7158 |
 MagSi-STA 600 |
|
MD16001 |
AMSBIO |
2 mL |
EUR 470.4 |
MagSi-STA 600 |
|
MD18001 |
AMSBIO |
10 mL |
EUR 1572 |
MagSi-STA 600 |
|
MD19001 |
AMSBIO |
100 mL |
EUR 9060 |
) Omaveloxolone (RTA-408) |
|
B3576-25 |
ApexBio |
25 mg |
EUR 332 |
|
|
|
Description: Apoptosis|KEAP1-Nrf2 |
Omaveloxolone (RTA-408) |
|
B3576-5 |
ApexBio |
5 mg |
EUR 108 |
|
|
|
Description: Apoptosis|KEAP1-Nrf2 |
 (AP)) EMD, CT (Emerin, STA, EDMD) (AP) |
|
MBS6473772-02mL |
MyBiosource |
0.2mL |
EUR 980 |
Our commitment is to critically review and publish papers designed to interpret the vast amounts of data available to physicians. As the famed radiotherapist and Founding Editor, Eli Glatstein, summarized, “The Oncologist emphasizes the interpretation rather than the data.” The Oncologist to date has published more than forty manuscripts from international authorities. The inaugural issue featured, among other highly acclaimed papers, “Locally Advanced Breast Cancer,” by Valero, Buzdar and Hortobagyi, and David Kuter’s “Thrombopoietin:
Biology and Clinical Applications.” Fidias, Chabner and Grossbard contributed “Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders” in the next issue, and Pavletic and Armitage proffered an update on “Bone Marrow Transplantation for Cancer.” Issue 4 highlighted Jemi Olak and Arthur Ng’s “Diagnosis and Management of Early-Stage Non-Small Cell Lung Cancer,” as well as “Multimodality Therapy for Esophageal Cancer” by Siewert, Stein and Fink. In this current issue, “Dose Intensity of Chemotherapy for Childhood Cancers,” by Smith, Abrams, Trimble and Ungerleider, and “Surgical Sphincter Preservation in Rectal Cancer” by Peter M.
Schlag present contemporary and authoritative views of two important clinical topics which also document the Journal’s intent to discuss both adult and pediatric cancer care. Our Meet The Professor section is fast becoming a popular feature which attracts comments from readers and responses from the author professor.
We call your attention to Professor Barrie R. Cassileth’s fascinating article, “Alternative and Complementary Cancer Treatments,” and her commentary in this issue.
The Physician Education section has presented hematopoiesis through informative and beautifully illustrated papers with texts by distinguished hematologists and molecular biologists. In this issue, we feature the first Patient Care section, From The Bethesda Post, wherein clinical trials and experimental treatments are announced. In cooperation with The Cancer Letter, The Oncologist News Bulletin presents late-breaking news pertinent to the world’s cancer care community.
With this issue, we have instituted an addition to this section, featuring information from Memorial Sloan-Kettering Cancer Center on a study involving Ashkenazi Jewish women. We urge cancer centers, pharmaceutical and biotechnology companies to avail themselves of this section by sending our editorial office your newsworthy reports. We hope that our readers are benefiting from the Journal and enjoying the art which has graced it. In order to assess how well we are fulfilling our pledges to our readership, we need to hear from you.
Tell us how we can make The Oncologist more relevant to your medical practice. We promise to share your comments with our Editorial Board to further enhance the Journal. In so doing, we will draw closer to fulfilling our pledge to you, our readers.
